EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Feasibility of an Intravenous Home Chemotherapy Intervention With Low‐Dose Cytarabine Administered by Parents (INTACTatHome)

Louise Ingerslev Roug iD, Lisa Lyngsie Hjalgrim, Tenna Ruest Haarmark Nielsen, Martha Krogh Topperzer, Mary Jarden, Anders Tolver, Astrid Eliasen iD, Ayo Wahlberg, Rikke Thenning Michelsen, Helena Hansson

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31965 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Louise Ingerslev Roug und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Cytarabine, Parents, Antimetabolites, Antineoplastic, Leukemia. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Danish Childhood Cancer Foundation, Novo Nordisk Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intravenous home chemotherapy (IHC) can reduce the frequency of hospital visits and positively affect the child's and the family's everyday life. Knowledge about IHC is needed to enhance evidence‐based provision and implementation. This study aimed to evaluate the feasibility of an IHC intervention. Procedure : Single‐arm feasibility study including children aged 1–17 years diagnosed with leukemia or lymphoma and their parents. The intervention consisted of an education program designed to enable parents to administer intravenous low‐dose cytarabine at home. Feasibility outcomes were families’ demand for the intervention, acceptability (satisfaction, preference, and caregiver demand), and safety. Data were collected from medical records, clinical registrations, and questionnaires and analyzed using descriptive statistics.

Results

Of the 17 children meeting the key inclusion criteria (mean age 5.1, range 2–15), 15 were enrolled. These children received a total of 175 low‐dose cytarabine administrations at home, constituting 56% of the planned doses. The continued home administration of cytarabine suggests sustained acceptability. Parents expressed high satisfaction with home administration and indicated a preference for it in future treatments. Caregiver demand scores showed no indication of increased caregiver demand during the IHC intervention. No severe adverse events were observed.

Conclusions

The IHC intervention is a feasible, acceptable, and safe option in this specific context, allowing children to receive intravenous chemotherapy administered by their parent in the comfort of their home.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytarabineParentsAntimetabolites, AntineoplasticLeukemiaLymphomaHome Care ServicesHumansChildChild, PreschoolAdolescentFemaleMaleFeasibility StudiesInfantCaregiversFollow-Up Studies

Stichwörter der Autor:innen

feasibility | home | low‐dose cytarabine | parents | pediatric cancer

Substanzen

CytarabineAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Department of Pediatric and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Culture and Communication, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Department of Hematology, Center for Cancer and Organ Disease, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Data Science Laboratory, Department of Mathematical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark.

ORCID-Profile: Louise Ingerslev Roug, Astrid Eliasen

Förderung

  • Danish Childhood Cancer Foundation
  • Novo Nordisk Foundation

Zitieren

APA

Ingerslev Roug, L., Lyngsie Hjalgrim, L., Nielsen, T. R. H., Krogh Topperzer, M., Jarden, M., Tolver, A., Eliasen, A., Wahlberg, A., Thenning Michelsen, R., & Hansson, H. (2025). Feasibility of an Intravenous Home Chemotherapy Intervention With Low‐Dose Cytarabine Administered by Parents (INTACTatHome). Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31965

Vancouver

Ingerslev Roug L, Lyngsie Hjalgrim L, Nielsen TRH, Krogh Topperzer M, Jarden M, Tolver A, et al. Feasibility of an Intravenous Home Chemotherapy Intervention With Low‐Dose Cytarabine Administered by Parents (INTACTatHome). Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31965

BibTeX
@article{IngerslevRoug2025,
  author = {Ingerslev Roug, Louise and Lyngsie Hjalgrim, Lisa and Nielsen, Tenna Ruest Haarmark and Krogh Topperzer, Martha and Jarden, Mary and Tolver, Anders and Eliasen, Astrid and Wahlberg, Ayo and Thenning Michelsen, Rikke and Hansson, Helena},
  title = {Feasibility of an Intravenous Home Chemotherapy Intervention With Low‐Dose Cytarabine Administered by Parents (INTACTatHome)},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31965}
}
Kostenlos starten →